Zoetis Shares Gain in Europe as Q3 Profit Beats Views

Zoetis Inc. saw its shares trade higher in Europe on Thursday, November 12. On Lang & Schwarz, the stock traded at 75.05 euros at 13:35 CET, marking a 2.69 percent gain compared to the previous Xetra close of 73.08 euros on Wednesday, November 11. In the United States, shares had previously gained 3.7% to close at $82.32 on November 09, 2026, though the stock has declined 33.1% year-to-date.

The recent trading activity follows the animal health company's third-quarter 2026 financial report. Zoetis posted adjusted earnings of $1.75 per share, topping the Zacks Consensus Estimate of $1.51 and increasing 3% year over year. Quarterly revenue reached $2.39 billion, exceeding expectations of $2.30 billion despite slipping 1% from the prior year. Chief financial officer and chief operating officer James Saccaro noted that lower revenue stemmed from a 1% price decline and flat shipment volumes, with domestic weakness balancing international gains.

Following the results, Zoetis adjusted its full-year financial projections. Management raised its 2026 adjusted earnings target to between $6.25 and $6.35 per share, alongside adjusted net income expectations of $2.60 to $2.64 billion. However, full-year revenue guidance was narrowed to $9.22-$9.32 billion, representing an organic operational drop of 1% to 2%. Saccaro indicated that fourth-quarter revenue is expected to drop by high single digits sequentially due to seasonality and promotion schedules, adding that the company is taking a conservative approach to 2027 planning.

Product lines showed contrasting results during the quarter. Dermatology revenue fell 16% to $396 million amid competitive headwinds, though targeted discounts helped slow U.S. market share erosion. Chief executive officer Kristin Peck stated that Simparica revenue increased 1% to $358 million, while osteoarthritis pain treatments generated $137 million, up 2%. The livestock segment provided stability with a 7% revenue gain to $797 million, and companion animal diagnostics jumped 13% to $122 million.

Valuation metrics have shifted alongside the company's recent operational performance. According to GuruFocus, the stock traded at a trailing price-to-earnings ratio of 14.0x, down from its five-year median of 33.8x. GuruFocus assigned Zoetis a GF Score of 71 out of 100, citing strong profitability metrics against weaker valuation and momentum scores. Zacks Investment Research currently holds a Rank #3 (Hold) on the stock, reflecting a balanced near-term outlook.